低剂量率远距离钴治疗作为食管癌的一种强化治疗手段。

Low-dose rate telecobalt therapy as a boost against esophageal carcinomas.

作者信息

Yamada S, Takai Y, Nemoto K, Ogawa Y, Kakuto Y, Hoshi A, Sakamoto K

机构信息

Department of Radiology, Tohoku University School of Medicine, Sendai, Japan.

出版信息

Cancer. 1992 Mar 1;69(5):1099-103. doi: 10.1002/cncr.2820690505.

DOI:10.1002/cncr.2820690505

PMID:1739907

Abstract

The results of treating 54 esophageal carcinomas with low-dose rate telecobalt therapy (LDRT) as a boost were compared with those of treating 97 esophageal carcinomas with conventionally fractionated irradiation alone (CFI). The LDRT (100 cGy/hr, 500 to 700 cGy/day, a total dose of 1400 to 2000 cGy) was boosted at 10 days after 6000 cGy of the CFI dose. Although the LDRT group included more advanced cases than the CFI group, local effects and survival rates in the former group were slightly better than in the latter group. Late complications were more severe in the LDRT group. However, they were acceptable when the total dose administered to this group was less than 8000 cGy. Using LDRT as a boost against esophageal carcinomas was found to be satisfactory therapeutically.

摘要

将54例食管癌患者采用低剂量率远距钴治疗（LDRT）作为加强治疗的结果，与97例仅采用常规分割照射（CFI）的食管癌患者的治疗结果进行了比较。LDRT（100 cGy/小时，500至700 cGy/天，总剂量1400至2000 cGy）在CFI剂量6000 cGy后的第10天进行加强治疗。尽管LDRT组比CFI组包含更多晚期病例，但前一组的局部疗效和生存率略优于后一组。LDRT组的晚期并发症更严重。然而，当该组给予的总剂量小于8000 cGy时，这些并发症是可以接受的。发现使用LDRT作为食管癌的加强治疗在治疗上是令人满意的。